Treatment of acute myeloid leukaemia in older patients – scope of intensive therapy? – A retrospective analysis

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Lazarevic V, Hörstedt A-S, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–3899. doi:10.1182/blood-2011-12-379008.
   PubMed Web of Science ®Google Scholar
• Sorensen JT, Gerald K, Bodensteiner D. Holmes FF effect of age on survival in acute leukemia. 1950–1990. Cancer. 1993;72(5):1602–1606.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422–4429. doi:10.1182/blood-2010-03-276485.
   PubMed Web of Science ®Google Scholar
• Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1–7. doi:10.1016/j.lrr.2016.06.001.
   PubMedGoogle Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114–1124. doi:10.1002/cncr.22496.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655. doi:10.1097/00000421-198212000-00014.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. doi:10.1182/blood-2005-05-2004.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi:10.3322/caac.21565.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR. Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34(4):101320. doi:10.1016/j.beha.2021.101320.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR. Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol. 2017;30(4):320–326. doi:10.1016/j.beha.2017.09.004.
   PubMed Web of Science ®Google Scholar
• Farag SS, Maharry K, Zhang M-J, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011;17(12):1796–1803. doi:10.1016/j.bbmt.2011.06.005.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with 30% blasts. Blood. 2015;126(3):291–299. doi:10.1182/blood-2015-01-621664.
   PubMed Web of Science ®Google Scholar
• Falantes J, Pleyer L, Thepot S, et al. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). Leuk Lymphoma. 2018;59(5):1113–1120. doi:10.1080/10428194.2017.1365854.
   PubMed Web of Science ®Google Scholar
• Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol. 2014;93(11):1825–1838. doi:10.1007/s00277-014-2126-9.
   PubMed Web of Science ®Google Scholar
• Dohner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546–2557. doi:10.1038/s41375-018-0257-z.
   PubMed Web of Science ®Google Scholar
• Ramos F, Thepot S, Pleyer L, et al. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res. 2015;39(3):296–306. doi:10.1016/j.leukres.2014.12.013.
   PubMed Web of Science ®Google Scholar
• Dumas P-Y, Bertoli S, Berard E, et al. Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia. Oncotarget. 2017;8(45):79126–79136. doi:10.18632/oncotarget.15988.
   PubMedGoogle Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731. doi:10.1182/blood-2017-04-779405.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi:10.1182/bloodadvances.2020002904.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi:10.1016/S2352-3026(21)00145-9.
   PubMed Web of Science ®Google Scholar
• Urbino I, Secreto C, Olivi M, et al. Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021. Cancers (Basel). 2021;13(20). doi:10.3390/cancers13205075.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971.
   PubMed Web of Science ®Google Scholar
• Foran JM. Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML? Best Pract Res Clin Haematol. 2021;34(4):101335. doi:10.1016/j.beha.2021.101335.
   PubMed Web of Science ®Google Scholar
• Prébet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747–4753. doi:10.1200/JCO.2008.21.0674.
   PubMed Web of Science ®Google Scholar
• Bazinet A, Kadia TM. Changing paradigms in the treatment of acute myeloid leukemia in older patients. Clin Adv Hematol Oncol. 2022;20(1):37–46.
   PubMed Web of Science ®Google Scholar
• Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–996. doi:10.1016/S1470-2045(14)70281-5.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840–851. doi:10.1182/blood-2018-08-869453.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389. doi:10.1038/s41375-018-0312-9.
   PubMed Web of Science ®Google Scholar